Clinical Trial Update: A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 safety study of Oraxol (HM30181 + oral paclitaxel) in cancer patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Oraxol

Snippet

Sponsor: Athenex, Inc. | Conditions: Solid Tumor | Phase 2 | Status: COMPLETED